HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Acrivon Therapeutics (NASDAQ:ACRV) and maintained a $22 price target.
August 13, 2024 | 6:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Acrivon Therapeutics and maintained a $22 price target.
The reiteration of a Buy rating and the maintenance of a $22 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100